Dicot

Shares and warrants in Dicot Pharma AB will be traded with unchanged short name (DICOT) and ISIN code (SE0011178458) and (DICOT TO 6) and ISIN code (SE0022600300) respectively. 

Shareholders in Dicot Pharma do not need to take any action in connection with the change of listing and there will be no offer or issue of new shares in connection with the change from Spotlight Stock Market to Nasdaq First North Growth Market.

The approval is subject to customary conditions and that Dicot Pharma publishes a supplementary document, which is intended to be published on the company's website around October 31, 2024.

"The change of listing to Nasdaq First North will benefit our continued development, internationalization and competitiveness. It is expected to increase awareness of Dicot Pharma and attract a broader group of investors and give the company better access to both the Swedish and international capital markets", comments Elin Trampe, CEO of Dicot Pharma.

FNCA Sweden AB has been appointed as Dicot Pharma's Certified Adviser on Nasdaq First North Stockholm.

For further information, please contact:

Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot Pharma is listed on Spotlight Stock Market and has approximately 7,200 shareholders. For more information, please visit www.dicotpharma.com.